

SURVODUTIDE 10 MG INJECTION
Drug Class: Dual Agonist (GLP-1 + Glucagon Receptor Agonist)
Composition:
- Active Substance: Survodutide
- Concentration: 10 mg/vial
Presentation: 2 mL Vial
Manufacturer: Dragon Pharma
Tested in Laboratory: View Lab Report
Survodutide is a dual agonist peptide targeting both GLP-1 (glucagon-like peptide-1) and glucagon receptors, developed to treat obesity and metabolic diseases. This 10 mg vial by Dragon Pharma delivers clinical-grade Survodutide designed to reduce body weight, improve insulin sensitivity, and regulate appetite.
Survodutide is currently in late-stage clinical trials and has demonstrated potent fat-reducing effects. See peer-reviewed data on Survodutide's metabolic and weight-loss benefits.
This innovative compound is being researched as a next-generation solution for patients unresponsive to semaglutide or tirzepatide.
Reconstitute with 1–2 mL of bacteriostatic water. Inject subcutaneously once per week. Initial dosing may begin at 2.5–5 mg weekly, with gradual increase to 10 mg or more, depending on tolerance and guidance from a health professional.
Best injected in the same area each week (abdomen or thigh), at the same time of day for consistency.
Survodutide can be combined with non-overlapping peptides for superior metabolic, recovery, or wellness results:
This GLP-1/glucagon dual-agonist peptide by Dragon Pharma is ideal for aggressive weight management and long-term metabolic control.
Common side effects include nausea, fullness, constipation, or fatigue during early use. These effects typically resolve as the body adapts. Survodutide is non-stimulant and non-addictive. Always use under the supervision of a qualified provider.
Survodutide 10 mg for Sale represents the future of advanced fat-loss peptide therapy. This high-potency Dragon Pharma peptide is trusted by clinicians and biohackers for safe, science-based metabolic enhancement.
Survodutide is a dual agonist peptide targeting GLP-1 and glucagon receptors. It is used to promote fat loss, control appetite, and improve metabolic health.
Clinical studies suggest Survodutide can result in significant body fat reduction, with weight loss comparable or superior to semaglutide and tirzepatide in some patients.
Survodutide is injected subcutaneously once weekly. Dosage typically begins low (2.5–5 mg) and is increased gradually based on tolerance and desired results.
Common side effects include nausea, fullness, or mild GI discomfort during the first few weeks. Most users adapt quickly with minimal ongoing issues.
Please log in to write Survodutide 10 mg review.
PENTADECAPEPTIDE 2 MG INJECTION
Drug Class: Healing/Repair Peptide
Composition:
- Active Substance: Pentadecapeptide
- Concentration: 5 mg/vial
Presentation: 5 mL Vial
Form: Powder
Manufacturer: Dragon Pharma
Tested in Laboratory: View Lab Report
TIRZE-PEP 5 MG INJECTION
Drug Class: Dual GLP-1/GIP Peptide
Composition:
- Active Substance: Tirzepatide
- Concentration: 5 mg/vial
Presentation: 2 mL Vial
Form: Powder
Manufacturer: Dragon Pharma
Tested in Laboratory: View Lab Report